re: Ann: CAVATAK anti-cancer activity - US Ca...
Evidence... the last trial was in late stage cancer patients most who had tried 3 different treatments already. These people were terminally ill. Fingers crossed, doesing patients who arn't quite so far along reepers even better results. This is very promising, especially seeing as we are now fully funded to the end of P3 trials. A bigger sample size. If results hold up we will be significantly derisked and will be demandind a much higher shareprice.
VLA Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
